Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity.
PD-1
Schweinfurthin
immunotherapy
melanoma
mice
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
Historique:
received:
24
07
2018
revised:
09
10
2018
accepted:
10
10
2018
entrez:
5
2
2019
pubmed:
5
2
2019
medline:
5
2
2019
Statut:
epublish
Résumé
Metastatic melanoma is a significant clinical problem with a 5-year survival rate of only 15-20%. Recent approval of new immunotherapies and targeted inhibitors have provided much needed options for these patients, in some cases promoting dramatic disease regressions. In particular, antibody-based therapies that block the PD-1/PD-L1 checkpoint inhibitory pathway have achieved an increased overall response rate in metastatic melanoma, yet durable response rates are reported only around 15%. To improve the overall and durable response rates for advanced-stage melanoma, combined targeted and immune-based therapies are under investigation. Here, we investigated how the natural products called schweinfurthins, which have selective anti-proliferative activity against many cancer types, impact anti-(α)PD-1-mediated immunotherapy of murine melanomas. Two different compounds efficiently reduced the growth of human and murine melanoma cells
Identifiants
pubmed: 30713799
doi: 10.1080/2162402X.2018.1539614
pii: 1539614
pmc: PMC6343772
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Pagination
e1539614Références
J Virol. 1999 Jul;73(7):5981-93
pubmed: 10364350
J Org Chem. 2005 Feb 4;70(3):925-31
pubmed: 15675850
J Immunol. 2005 May 15;174(10):6477-89
pubmed: 15879151
Cell. 2005 Oct 21;123(2):321-34
pubmed: 16239148
Bioorg Med Chem. 2006 Mar 15;14(6):1771-84
pubmed: 16290161
Bioorg Med Chem Lett. 2007 Feb 15;17(4):911-5
pubmed: 17236766
J Nat Prod. 2007 Mar;70(3):342-6
pubmed: 17326683
J Nat Prod. 2008 Nov;71(11):1949-52
pubmed: 18922035
Bioorg Med Chem. 2009 Jul 1;17(13):4718-23
pubmed: 19464190
Bioorg Med Chem. 2010 Feb 15;18(4):1676-83
pubmed: 20116262
Mol Cancer Ther. 2010 May;9(5):1234-43
pubmed: 20442305
Bioorg Med Chem Lett. 2010 Nov 15;20(22):6716-20
pubmed: 20869871
Lipids. 2011 Oct;46(10):907-21
pubmed: 21633866
Nat Chem Biol. 2011 Aug 07;7(9):639-47
pubmed: 21822274
Cytometry A. 2012 Apr;81(4):343-50
pubmed: 22213571
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
PLoS One. 2013 Apr 12;8(4):e60975
pubmed: 23593363
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846
J Org Chem. 2013 Sep 20;78(18):9291-302
pubmed: 24004185
Oncoimmunology. 2013 Sep 1;2(9):e25770
pubmed: 24327936
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
Bioorg Med Chem. 2014 Apr 15;22(8):2542-52
pubmed: 24656801
Cold Spring Harb Symp Quant Biol. 2013;78:239-47
pubmed: 25028401
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Immunity. 2014 Nov 20;41(5):830-42
pubmed: 25517615
Cancer Biol Ther. 2015;16(4):589-601
pubmed: 25729885
Sci Transl Med. 2015 Mar 18;7(279):279ra41
pubmed: 25787767
Sci Signal. 2015 Mar 31;8(370):re4
pubmed: 25829448
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Lipids. 2015 Dec;50(12):1195-207
pubmed: 26494560
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Immunity. 2016 Feb 16;44(2):343-54
pubmed: 26872698
Nature. 2016 Mar 31;531(7596):651-5
pubmed: 26982734
J Natl Cancer Inst. 1989 Jul 19;81(14):1088-92
pubmed: 2738938
Oncologist. 2016 Oct;21(10):1230-1240
pubmed: 27401894
Immunology. 2016 Dec;149(4):432-446
pubmed: 27548304
Cell Death Differ. 2016 Dec;23(12):2031-2041
pubmed: 27588704
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Oncoimmunology. 2016 Oct 14;5(12):e1238557
pubmed: 28123875
J Immunol Methods. 2017 Jul;446:47-53
pubmed: 28390927
Cell Death Dis. 2017 May 25;8(5):e2824
pubmed: 28542128
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Anticancer Res. 2017 Jul;37(7):3863-3869
pubmed: 28668887
Cancer Res. 2017 Oct 15;77(20):5639-5651
pubmed: 28819022
Cell. 2017 Sep 7;170(6):1109-1119.e10
pubmed: 28886381
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
J Orthop Res. 2018 Apr;36(4):1283-1293
pubmed: 28960476
Oncotarget. 2017 Jun 27;8(42):71965-71980
pubmed: 29069761
Ann Oncol. 2018 Jan 1;29(1):84-91
pubmed: 29228097
Front Immunol. 2017 Nov 27;8:1664
pubmed: 29230226
Front Immunol. 2017 Dec 01;8:1714
pubmed: 29250078
Front Immunol. 2017 Dec 04;8:1597
pubmed: 29255458
J Clin Oncol. 2018 Jun 10;36(17):1668-1674
pubmed: 29283791
Cell. 2018 Feb 8;172(4):825-840.e18
pubmed: 29336888
Oncoimmunology. 2017 Dec 21;7(3):e1405205
pubmed: 29399407
J Exp Med. 2018 Jun 4;215(6):1555-1569
pubmed: 29743292
Oncoimmunology. 2018 Mar 15;7(6):e1433981
pubmed: 29872568
J Nat Prod. 1998 Dec;61(12):1509-12
pubmed: 9868152